Posted by Michael Wonder on 26 Sep 2023
Dupixent (dupilimab) sBLA for treatment of eosinophilic oesophagitis in children aged 1 to 11 accepted for FDA priority review
26 September 2023 - If approved, Dupixent would be the first and only treatment in the US indicated for children aged 1 to 11 with eosinophilic oesophagitis, a disease driven by type 2 inflammation that impacts the ability to eat.
Regeneron Pharmaceuticals and Sanofi today announced that the US FDA has accepted for priority review the supplemental biologics license application for Dupixent (dupilumab) to treat children aged 1 to 11 years with eosinophilic oesophagitis.
